SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-007782
Filing Date
2024-05-10
Accepted
2024-05-10 16:05:50
Documents
54
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q sngx-20240331x10q.htm   iXBRL 10-Q 1201753
2 EX-31.1 sngx-20240331xex31d1.htm EX-31.1 18445
3 EX-31.2 sngx-20240331xex31d2.htm EX-31.2 18503
4 EX-32.1 sngx-20240331xex32d1.htm EX-32.1 8289
5 EX-32.2 sngx-20240331xex32d2.htm EX-32.2 9972
  Complete submission text file 0001558370-24-007782.txt   5354323

Data Files

Seq Description Document Type Size
6 EX-101.SCH sngx-20240331.xsd EX-101.SCH 32917
7 EX-101.CAL sngx-20240331_cal.xml EX-101.CAL 40714
8 EX-101.DEF sngx-20240331_def.xml EX-101.DEF 185727
9 EX-101.LAB sngx-20240331_lab.xml EX-101.LAB 340032
10 EX-101.PRE sngx-20240331_pre.xml EX-101.PRE 270283
58 EXTRACTED XBRL INSTANCE DOCUMENT sngx-20240331x10q_htm.xml XML 731994
Mailing Address 29 EMMONS DRIVE SUITE B-10 PRINCETON NJ 08540
Business Address 29 EMMONS DRIVE SUITE B-10 PRINCETON NJ 08540 609-538-8200
SOLIGENIX, INC. (Filer) CIK: 0000812796 (see all company filings)

IRS No.: 411505029 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-14778 | Film No.: 24934796
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)